View Future GrowthBiofarm 과거 순이익 실적과거 기준 점검 5/6Biofarm은 연평균 9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.8% 증가했습니다. 매출은 연평균 6.2%의 비율로 증가했습니다. Biofarm의 자기자본이익률은 17.4%이고 순이익률은 31.7%입니다.핵심 정보9.05%순이익 성장률9.05%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률12.39%매출 성장률6.21%자기자본이익률17.36%순이익률31.70%다음 순이익 업데이트14 Aug 2026최근 과거 실적 업데이트분석 기사 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...Reported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.46, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 150% over the past three years.공시 • May 08Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion.Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion on May 6, 2026. A cash consideration valued at RON 1.379 per share will be paid by Polpharma SA Pharmaceutical Works, nearly 15% above the market price at the time the announcement was made. The price of Biofarm’s shares increased by 2.9% on May 7, 2026. Each of Longshield Investment Group SA and Lion Capital S.A. have undertaken to tender in such VTO all of their shares held in Biofarm. Separately, Lion Capital S.A. as shareholder of Biofarm S.A. entered into an implementation agreement with Longshield Investment Group S.A. and Zaklady Farmaceutyczne Polpharma S.A. The launch of the VTO is subject to obtaining all relevant approvals from the Financial Supervisory Authority. A special dividend of RON 0.140263 per share is intended to be distributed to all of the legally entitled shareholders of Biofarm, subject to approval by the general meeting of its shareholders before the launch of the VTO.Upcoming Dividend • May 06Upcoming dividend of RON0.042 per shareEligible shareholders must have bought the stock before 13 May 2026. Payment date: 29 May 2026. Payout ratio is a comfortable 41% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Romanian dividend payers (6.6%). Higher than average of industry peers (2.8%).분석 기사 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...공시 • Mar 26Biofarm S.A. announces Annual dividend, payable on May 29, 2026Biofarm S.A. announced Annual dividend of RON 0.0420 per share payable on May 29, 2026, ex-date on May 13, 2026 and record date on May 14, 2026.공시 • Mar 24Biofarm S.A., Annual General Meeting, Apr 28, 2026Biofarm S.A., Annual General Meeting, Apr 28, 2026, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99 logofatul tautu street, 3rd district., RomaniaReported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.34, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 125% over the past three years.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 26%After last week's 26% share price gain to RON1.05, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 82% over the past three years.공시 • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Aug 11Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 18 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Romanian dividend payers (6.3%). Higher than average of industry peers (3.1%).Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.Declared Dividend • Mar 24Dividend of RON0.031 announcedDividend of RON0.031 is the same as last year. Ex-date: 18th August 2025 Payment date: 5th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but not covered by cash flows (125% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Mar 23Biofarm S.A. announces Annual dividend, payable on September 05, 2025Biofarm S.A. announced Annual dividend of RON 0.0310 per share payable on September 05, 2025, ex-date on August 18, 2025 and record date on August 19, 2025.공시 • Mar 21Biofarm S.A., Annual General Meeting, Apr 28, 2025Biofarm S.A., Annual General Meeting, Apr 28, 2025, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99, logofatul tautu street, 3rd district., bucharest RomaniaNew Risk • Mar 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RON67.2m (US$14.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 06Full year 2024 earnings released: EPS: RON0.076 (vs RON0.078 in FY 2023)Full year 2024 results: EPS: RON0.076 (down from RON0.078 in FY 2023). Revenue: RON287.2m (up 2.5% from FY 2023). Net income: RON74.4m (down 3.4% from FY 2023). Profit margin: 26% (down from 28% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON70.0m (up 5.5% from 2Q 2023). Net income: RON21.4m (up 16% from 2Q 2023). Profit margin: 31% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue.Upcoming Dividend • Aug 13Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 20 August 2024. Payment date: 06 September 2024. Payout ratio is a comfortable 46% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.2%).Reported Earnings • Apr 30Full year 2023 earnings released: EPS: RON0.078 (vs RON0.072 in FY 2022)Full year 2023 results: EPS: RON0.078 (up from RON0.072 in FY 2022). Revenue: RON280.3m (up 1.2% from FY 2022). Net income: RON77.0m (up 8.6% from FY 2022). Profit margin: 28% (up from 26% in FY 2022). The increase in margin was primarily driven by lower expenses. Post-clinical trial products Launched (during full year): 11 Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON67.3m (down 4.3% from 3Q 2022). Net income: RON19.8m (down 10% from 3Q 2022). Profit margin: 30% (down from 31% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Non-Executive Non-Independent Director Marian Buica Nicusor was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON66.5m (up 6.0% from 2Q 2022). Net income: RON18.5m (up 8.5% from 2Q 2022). Profit margin: 28% (in line with 2Q 2022).Upcoming Dividend • Aug 14Upcoming dividend of RON0.03 per share at 4.3% yieldEligible shareholders must have bought the stock before 21 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 39% and the cash payout ratio is 85%. Trailing yield: 4.3%. Lower than top quartile of Romanian dividend payers (8.4%). Higher than average of industry peers (2.5%).Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON71.0m (up 17% from 3Q 2021). Net income: RON22.1m (up 20% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021).Buying Opportunity • Aug 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.Upcoming Dividend • Aug 15Upcoming dividend of RON0.024 per shareEligible shareholders must have bought the stock before 22 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.8%).Buying Opportunity • May 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.061 (up from RON0.055 in FY 2020). Revenue: RON240.3m (up 11% from FY 2020). Net income: RON60.0m (up 11% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Aug 09Upcoming dividend of RON0.022 per shareEligible shareholders must have bought the stock before 16 August 2021. Payment date: 03 September 2021. Trailing yield: 3.7%. Lower than top quartile of Romanian dividend payers (5.6%). Higher than average of industry peers (2.7%).Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: RON62.8m (down 2.0% from 1Q 2020). Net income: RON22.5m (up 21% from 1Q 2020). Profit margin: 36% (up from 29% in 1Q 2020). The increase in margin was driven by lower expenses.분석 기사 • Mar 18Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...분석 기사 • Feb 18Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Is New 90 Day High Low • Feb 17New 90-day high: RON0.53The company is up 28% from its price of RON0.41 on 19 November 2020. The Romanian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.분석 기사 • Jan 23Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total ReturnWhen we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...Is New 90 Day High Low • Jan 11New 90-day high: RON0.45The company is up 10.0% from its price of RON0.41 on 13 October 2020. The Romanian market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.분석 기사 • Dec 25A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)Today we will run through one way of estimating the intrinsic value of Biofarm S.A. ( BVB:BIO ) by taking the expected...Is New 90 Day High Low • Dec 22New 90-day high: RON0.42The company is up 3.0% from its price of RON0.40 on 23 September 2020. The Romanian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.분석 기사 • Dec 03Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?The big shareholder groups in Biofarm S.A. ( BVB:BIO ) have power over the company. Institutions often own shares in...Is New 90 Day High Low • Oct 16New 90-day low: RON0.39The company is down 5.0% from its price of RON0.41 on 17 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.Is New 90 Day High Low • Sep 30New 90-day low: RON0.40The company is down 2.0% from its price of RON0.41 on 02 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.매출 및 비용 세부 내역Biofarm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BVB:BIO 매출, 비용 및 순이익 (RON Millions)날짜매출순이익일반관리비연구개발비31 Mar 26318101120031 Dec 25319101120030 Sep 2531988118030 Jun 2530981117031 Mar 2531086125031 Dec 2428774109030 Sep 2428280104030 Jun 2425969103031 Mar 242566694031 Dec 2328077110030 Sep 2329775117030 Jun 2330177116031 Mar 2329776112031 Dec 2227771106030 Sep 2226971101030 Jun 222606898031 Mar 222536594031 Dec 212396090030 Sep 212416490030 Jun 212316186031 Mar 212155880031 Dec 202165482030 Sep 202145680030 Jun 202055281031 Mar 202115388031 Dec 191955175030 Sep 191894288030 Jun 191954464031 Mar 191894365031 Dec 181843864030 Sep 181794361030 Jun 181713864031 Mar 181763959031 Dec 171703658030 Sep 171673553030 Jun 171653555031 Mar 171553252031 Dec 161522952030 Sep 161492945030 Jun 161482758031 Mar 161382044031 Dec 151492744030 Sep 151472748030 Jun 1513827340양질의 수익: BIO는 고품질 수익을 보유하고 있습니다.이익 마진 증가: BIO의 현재 순 이익률 (31.7%)은 지난해 (27.7%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIO의 수익은 지난 5년 동안 연평균 9% 증가했습니다.성장 가속화: 지난 1년간 BIO 의 수익 증가율(17.1%)은 연간 평균(9%)을 초과합니다.수익 대 산업: BIO의 지난 1년 수익 증가율(17.1%)은 Pharmaceuticals 업계의 16.1%를 상회했습니다.자기자본이익률높은 ROE: BIO의 자본 수익률(17.4%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 13:24종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biofarm S.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Vladimira UrbankovaErste Group Bank AGRaluca FloreaErste Group Bank AG
분석 기사 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...
Reported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.46, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 150% over the past three years.
공시 • May 08Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion.Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. (BVB:BIO) from Longshield Investment Group SA (BVB:LONG), Lion Capital S.A. (BVB:LION) and other shareholders for RON 1.4 billion on May 6, 2026. A cash consideration valued at RON 1.379 per share will be paid by Polpharma SA Pharmaceutical Works, nearly 15% above the market price at the time the announcement was made. The price of Biofarm’s shares increased by 2.9% on May 7, 2026. Each of Longshield Investment Group SA and Lion Capital S.A. have undertaken to tender in such VTO all of their shares held in Biofarm. Separately, Lion Capital S.A. as shareholder of Biofarm S.A. entered into an implementation agreement with Longshield Investment Group S.A. and Zaklady Farmaceutyczne Polpharma S.A. The launch of the VTO is subject to obtaining all relevant approvals from the Financial Supervisory Authority. A special dividend of RON 0.140263 per share is intended to be distributed to all of the legally entitled shareholders of Biofarm, subject to approval by the general meeting of its shareholders before the launch of the VTO.
Upcoming Dividend • May 06Upcoming dividend of RON0.042 per shareEligible shareholders must have bought the stock before 13 May 2026. Payment date: 29 May 2026. Payout ratio is a comfortable 41% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Romanian dividend payers (6.6%). Higher than average of industry peers (2.8%).
분석 기사 • Apr 01Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...
공시 • Mar 26Biofarm S.A. announces Annual dividend, payable on May 29, 2026Biofarm S.A. announced Annual dividend of RON 0.0420 per share payable on May 29, 2026, ex-date on May 13, 2026 and record date on May 14, 2026.
공시 • Mar 24Biofarm S.A., Annual General Meeting, Apr 28, 2026Biofarm S.A., Annual General Meeting, Apr 28, 2026, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99 logofatul tautu street, 3rd district., Romania
Reported Earnings • Mar 04Full year 2025 earnings released: EPS: RON0.10 (vs RON0.076 in FY 2024)Full year 2025 results: EPS: RON0.10 (up from RON0.076 in FY 2024). Revenue: RON330.4m (up 15% from FY 2024). Net income: RON100.8m (up 36% from FY 2024). Profit margin: 31% (up from 26% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON1.34, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 125% over the past three years.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improves as stock rises 26%After last week's 26% share price gain to RON1.05, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 82% over the past three years.
공시 • Jan 14+ 3 more updatesBiofarm S.A. to Report Q4, 2025 Results on Feb 27, 2026Biofarm S.A. announced that they will report Q4, 2025 results on Feb 27, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: RON100.8m (up 12% from 3Q 2024). Net income: RON38.3m (up 22% from 3Q 2024). Profit margin: 38% (up from 35% in 3Q 2024). The increase in margin was driven by higher revenue.
Reported Earnings • Aug 16Second quarter 2025 earnings released: EPS: RON0.017 (vs RON0.022 in 2Q 2024)Second quarter 2025 results: EPS: RON0.017 (down from RON0.022 in 2Q 2024). Revenue: RON68.3m (down 2.0% from 2Q 2024). Net income: RON16.5m (down 23% from 2Q 2024). Profit margin: 24% (down from 31% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Aug 11Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 18 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Romanian dividend payers (6.3%). Higher than average of industry peers (3.1%).
Reported Earnings • May 16First quarter 2025 earnings released: EPS: RON0.033 (vs RON0.021 in 1Q 2024)First quarter 2025 results: EPS: RON0.033 (up from RON0.021 in 1Q 2024). Revenue: RON95.1m (up 33% from 1Q 2024). Net income: RON32.3m (up 57% from 1Q 2024). Profit margin: 34% (up from 29% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year.
Declared Dividend • Mar 24Dividend of RON0.031 announcedDividend of RON0.031 is the same as last year. Ex-date: 18th August 2025 Payment date: 5th September 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but not covered by cash flows (125% cash payout ratio). The dividend has increased by an average of 7.5% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 7.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Mar 23Biofarm S.A. announces Annual dividend, payable on September 05, 2025Biofarm S.A. announced Annual dividend of RON 0.0310 per share payable on September 05, 2025, ex-date on August 18, 2025 and record date on August 19, 2025.
공시 • Mar 21Biofarm S.A., Annual General Meeting, Apr 28, 2025Biofarm S.A., Annual General Meeting, Apr 28, 2025, at 12:00 E. Europe Standard Time. Location: at the company office in bucharest, no. 99, logofatul tautu street, 3rd district., bucharest Romania
New Risk • Mar 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RON67.2m (US$14.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 06Full year 2024 earnings released: EPS: RON0.076 (vs RON0.078 in FY 2023)Full year 2024 results: EPS: RON0.076 (down from RON0.078 in FY 2023). Revenue: RON287.2m (up 2.5% from FY 2023). Net income: RON74.4m (down 3.4% from FY 2023). Profit margin: 26% (down from 28% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.
Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON70.0m (up 5.5% from 2Q 2023). Net income: RON21.4m (up 16% from 2Q 2023). Profit margin: 31% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue.
Upcoming Dividend • Aug 13Upcoming dividend of RON0.031 per shareEligible shareholders must have bought the stock before 20 August 2024. Payment date: 06 September 2024. Payout ratio is a comfortable 46% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.2%).
Reported Earnings • Apr 30Full year 2023 earnings released: EPS: RON0.078 (vs RON0.072 in FY 2022)Full year 2023 results: EPS: RON0.078 (up from RON0.072 in FY 2022). Revenue: RON280.3m (up 1.2% from FY 2022). Net income: RON77.0m (up 8.6% from FY 2022). Profit margin: 28% (up from 26% in FY 2022). The increase in margin was primarily driven by lower expenses. Post-clinical trial products Launched (during full year): 11 Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: RON67.3m (down 4.3% from 3Q 2022). Net income: RON19.8m (down 10% from 3Q 2022). Profit margin: 30% (down from 31% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Non-Executive Non-Independent Director Marian Buica Nicusor was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: RON66.5m (up 6.0% from 2Q 2022). Net income: RON18.5m (up 8.5% from 2Q 2022). Profit margin: 28% (in line with 2Q 2022).
Upcoming Dividend • Aug 14Upcoming dividend of RON0.03 per share at 4.3% yieldEligible shareholders must have bought the stock before 21 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 39% and the cash payout ratio is 85%. Trailing yield: 4.3%. Lower than top quartile of Romanian dividend payers (8.4%). Higher than average of industry peers (2.5%).
Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: RON71.0m (up 17% from 3Q 2021). Net income: RON22.1m (up 20% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021).
Buying Opportunity • Aug 22Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.
Upcoming Dividend • Aug 15Upcoming dividend of RON0.024 per shareEligible shareholders must have bought the stock before 22 August 2022. Payment date: 09 September 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Romanian dividend payers (7.1%). Higher than average of industry peers (2.8%).
Buying Opportunity • May 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be RON0.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 12%.
Reported Earnings • Mar 03Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.061 (up from RON0.055 in FY 2020). Revenue: RON240.3m (up 11% from FY 2020). Net income: RON60.0m (up 11% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Aug 09Upcoming dividend of RON0.022 per shareEligible shareholders must have bought the stock before 16 August 2021. Payment date: 03 September 2021. Trailing yield: 3.7%. Lower than top quartile of Romanian dividend payers (5.6%). Higher than average of industry peers (2.7%).
Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: RON62.8m (down 2.0% from 1Q 2020). Net income: RON22.5m (up 21% from 1Q 2020). Profit margin: 36% (up from 29% in 1Q 2020). The increase in margin was driven by lower expenses.
분석 기사 • Mar 18Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...
분석 기사 • Feb 18Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Is New 90 Day High Low • Feb 17New 90-day high: RON0.53The company is up 28% from its price of RON0.41 on 19 November 2020. The Romanian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
분석 기사 • Jan 23Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total ReturnWhen we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
Is New 90 Day High Low • Jan 11New 90-day high: RON0.45The company is up 10.0% from its price of RON0.41 on 13 October 2020. The Romanian market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
분석 기사 • Dec 25A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)Today we will run through one way of estimating the intrinsic value of Biofarm S.A. ( BVB:BIO ) by taking the expected...
Is New 90 Day High Low • Dec 22New 90-day high: RON0.42The company is up 3.0% from its price of RON0.40 on 23 September 2020. The Romanian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
분석 기사 • Dec 03Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?The big shareholder groups in Biofarm S.A. ( BVB:BIO ) have power over the company. Institutions often own shares in...
Is New 90 Day High Low • Oct 16New 90-day low: RON0.39The company is down 5.0% from its price of RON0.41 on 17 July 2020. The Romanian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Sep 30New 90-day low: RON0.40The company is down 2.0% from its price of RON0.41 on 02 July 2020. The Romanian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.